Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.

Lambert JS, Else LJ, Jackson V, Breiden J, Gibbons S, Dickinson L, Back DJ, Brennan M, Connor EO, Boyle N, Fleming C, Coulter-Smith S, Khoo SH.

HIV Med. 2011 Mar;12(3):166-73. doi: 10.1111/j.1468-1293.2010.00865.x. Epub 2010 Aug 18.

2.

Reduced lopinavir exposure during pregnancy.

Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS.

AIDS. 2006 Oct 3;20(15):1931-9.

PMID:
16988514
3.
4.

Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1.

Falkensammer B, Fasser W, Scherer K, Zemann A, Parson W, Ulmer H, Dierich MP, Stoiber H.

Int J Immunopathol Pharmacol. 2005 Jan-Mar;18(1):145-54.

PMID:
15698519
5.

Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.

Decloedt EH, McIlleron H, Smith P, Merry C, Orrell C, Maartens G.

Antimicrob Agents Chemother. 2011 Jul;55(7):3195-200. doi: 10.1128/AAC.01598-10. Epub 2011 May 2.

6.

Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.

Rosso R, Di Biagio A, Dentone C, Gattinara GC, Martino AM, Viganò A, Merlo M, Giaquinto C, Rampon O, Bassetti M, Gatti G, Viscoli C.

J Antimicrob Chemother. 2006 Jun;57(6):1168-71. Epub 2006 Apr 10.

7.

Steady-state lopinavir levels in third trimester of pregnancy.

Lyons F, Lechelt M, De Ruiter A.

AIDS. 2007 May 11;21(8):1053-4.

PMID:
17457104
8.

Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.

Baroncelli S, Villani P, Floridia M, Pirillo MF, Galluzzo CM, Cusato M, Amici R, Pinnetti C, Sabbatini F, Molinari A, Tamburrini E, Regazzi M.

Ther Drug Monit. 2008 Oct;30(5):604-10. doi: 10.1097/FTD.0b013e3181867a6e.

PMID:
18728627
9.

Lopinavir exposure with an increased dose during pregnancy.

Mirochnick M, Best BM, Stek AM, Capparelli E, Hu C, Burchett SK, Holland DT, Smith E, Gaddipati S, Read JS; PACTG 1026s Study Team.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):485-91. doi: 10.1097/QAI.0b013e318186edd0.

10.

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.

Masquelier B, Breilh D, Neau D, Lawson-Ayayi S, Lavignolle V, Ragnaud JM, Dupon M, Morlat P, Dabis F, Fleury H; Groupe d' Epidémiologie Clinique du SIDA en Aquitaine.

Antimicrob Agents Chemother. 2002 Sep;46(9):2926-32.

11.

Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.

Calza L, Manfredi R, Trapani F, Salvadori C, Colangeli V, Borderi M, Grossi G, Motta R, Viale P.

Scand J Infect Dis. 2012 May;44(5):381-7. doi: 10.3109/00365548.2011.642306. Epub 2012 Jan 21.

PMID:
22263609
12.

Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations.

Gutiérrez F, Padilla S, Masiá M, Navarro A, Gallego J, Hernández I, Ramos JM, Martin-Hidalgo A.

Antivir Ther. 2004 Feb;9(1):105-13.

PMID:
15040542
13.

The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.

Kohlrausch FB, de Cássia Estrela R, Barroso PF, Suarez-Kurtz G.

Br J Clin Pharmacol. 2010 Jan;69(1):95-8. doi: 10.1111/j.1365-2125.2009.03551.x.

14.

Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy.

Ramautarsing RA, van der Lugt J, Gorowara M, Kerr SJ, Burger D, Ruxrungtham K, Phanuphak P, Chaithongwongwatthana S, Avihingsanon A, Phanuphak N.

AIDS. 2011 Jun 19;25(10):1299-303. doi: 10.1097/QAD.0b013e328347f7e9.

PMID:
21516029
15.

Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen.

Azria E, Moutafoff C, Schmitz T, Le Meaux JP, Krivine A, Pannier E, Firtion G, Compagnucci A, Finkielsztejn L, Taulera O, Tsatsaris V, Cabrol D, Launay O.

Antivir Ther. 2009;14(3):423-32.

PMID:
19474476
16.

Determination of lopinavir and ritonavir in blood plasma, seminal plasma, saliva and plasma ultra-filtrate by liquid chromatography/tandem mass spectrometry detection.

Estrela RC, Ribeiro FS, Seixas BV, Suarez-Kurtz G.

Rapid Commun Mass Spectrom. 2008;22(5):657-64. doi: 10.1002/rcm.3411.

PMID:
18257112
17.

Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir.

Caswell RJ, Phillips D, Chaponda M, Khoo SH, Taylor GP, Ghanem M, Poulton M, Welch J, Gibbons S, Jackson V, Lambert JS.

Int J STD AIDS. 2011 Jan;22(1):11-4. doi: 10.1258/ijsa.2009.009184.

18.

Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.

Ghosn J, Chaix ML, Peytavin G, Bresson JL, Galimand J, Girard PM, Raffi F, Cohen-Codar I, Delfraissy JF, Rouzioux C.

J Antimicrob Chemother. 2008 Jun;61(6):1344-7. doi: 10.1093/jac/dkn098. Epub 2008 Mar 13.

19.

Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens.

Gutiérrez F, Padilla S, Navarro A, Masiá M, Hernández I, Ramos J, Esteban A, Martin-Hidalgo A.

J Acquir Immune Defic Syndr. 2003 Aug 15;33(5):594-600.

PMID:
12902803
20.

Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.

Else LJ, Jackson V, Brennan M, Back DJ, Khoo SH, Coulter-Smith S, Lambert JS.

HIV Med. 2014 Nov;15(10):604-10. doi: 10.1111/hiv.12164. Epub 2014 May 14.

PMID:
24825070
Items per page

Supplemental Content

Write to the Help Desk